Synonyms: Arlansa® | SCH 900518 | SCH-900518 | SCH900518
narlaprevir is an approved drug (Russia (2016))
Compound class:
Synthetic organic
Comment: Narlaprevir (SCH90051) is an oral HCV NS3 serine protease inhibitor [1,3]. It is structurally related to boceprevir. Narlaprevir forms a reversible covalent bond with the protease's active-site serine. It has also been reported to inhibit SARS-CoV-2 coronavirus main cysteine protease (3CLpro or Mpro) in vitro [2].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. Russia (2016) |
IUPAC Name ![]() |
narlaprevir |
International Nonproprietary Names ![]() |
|
INN number | INN |
9227 | narlaprevir |
Synonyms ![]() |
Arlansa® | SCH 900518 | SCH-900518 | SCH900518 |
Database Links ![]() |
|
CAS Registry No. | 865466-24-6 (source: PubChem) |
ChEMBL Ligand | CHEMBL1255891 |
GtoPdb PubChem SID | 441604944 |
PubChem CID | 11857239 |
Search Google for chemical match using the InChIKey | RICZEKWVNZFTNZ-LFGITCQGSA-N |
Search Google for chemicals with the same backbone | RICZEKWVNZFTNZ |
Search PubMed clinical trials | narlaprevir |
Search PubMed titles | narlaprevir |
Search PubMed titles/abstracts | narlaprevir |
UniChem Compound Search for chemical match using the InChIKey | RICZEKWVNZFTNZ-LFGITCQGSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | RICZEKWVNZFTNZ-LFGITCQGSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Narlaprevir (links to external site)
Cat. No. HY-10300 |